Figure 7.

HARPS in TNBC

(A) Two-way scatterplot of HER2 Y1248 (y axis) and EGFR Y1173 (x axis) of TNBC patients (n = 252) with pre-defined neratinib response cut-point (blue solid line).¹⁴

(B) Response rates observed for TNBC patients whose tumors were HARPS+ or HARPS– across the six treatments arms for TNBC patients.

(C) Donut plots of the TN RPS signature distribution in both the HARPS+ and HARPS– cohorts. Numbers indicate individual patient numbers for each signature with overall number shown in the middle of circle.